As Australian shares inch closer to the 9,000-point mark with a modest gain, market participants are keeping a keen eye on local developments such as the Viva Energy refinery incident that could impact fuel supplies. In this environment of cautious optimism and potential volatility, identifying stocks that may be trading below their estimated value can offer investors opportunities to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Australia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Wrkr (ASX:WRK) |
A$0.11 |
A$0.20 |
45% |
| ReadyTech Holdings (ASX:RDY) |
A$1.225 |
A$2.42 |
49.5% |
| Nuix (ASX:NXL) |
A$1.255 |
A$2.47 |
49.2% |
| Nick Scali (ASX:NCK) |
A$15.78 |
A$29.43 |
46.4% |
| Magellan Financial Group (ASX:MFG) |
A$9.48 |
A$17.68 |
46.4% |
| LGI (ASX:LGI) |
A$3.81 |
A$6.89 |
44.7% |
| Kogan.com (ASX:KGN) |
A$4.07 |
A$7.99 |
49.1% |
| Integral Diagnostics (ASX:IDX) |
A$2.31 |
A$4.53 |
49% |
| Cogstate (ASX:CGS) |
A$2.40 |
A$4.72 |
49.1% |
| Betmakers Technology Group (ASX:BET) |
A$0.175 |
A$0.31 |
44% |
Let's review some notable picks from our screened stocks.
Cogstate
Overview:Cogstate Limited is a neuroscience solutions company focused on developing and commercializing digital brain health assessments globally, with a market cap of A$410.01 million.
Operations:The company's revenue is derived from two main segments: Healthcare (including Sport), which contributes $2.48 million, and Clinical Trials (including Precision Recruitment Tool & Research), generating $53.59 million.
Estimated Discount To Fair Value:49.1%
Cogstate Limited appears undervalued, trading at 49.1% below its estimated fair value of A$4.72 based on discounted cash flow analysis. With revenue guidance for the second half of fiscal year 2026 showing a record A$21.7 million in contracted revenue and an expected annual earnings growth rate of 24.5%, Cogstate's financials present a strong case for future profitability relative to market averages, despite high non-cash earnings levels.
Integral Diagnostics
Overview:Integral Diagnostics Limited is a healthcare services company offering diagnostic imaging services to medical professionals and patients in Australia and New Zealand, with a market cap of A$860.45 million.
Operations:The company generates revenue of A$767.82 million from operating diagnostic imaging facilities across Australia and New Zealand.
Estimated Discount To Fair Value:49%
Integral Diagnostics is trading at A$2.31, significantly below its estimated future cash flow value of A$4.53, suggesting it may be undervalued based on discounted cash flow analysis. Despite a low forecasted return on equity and revenue growth slower than 20% annually, earnings are expected to grow 33.3% per year, outpacing the Australian market's average growth rate of 12.2%. Recent leadership changes aim to support strategic M&A activities and continued business expansion.
Nuix
Overview:Nuix Limited offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa, with a market cap of A$420.62 million.
Operations:The company generates revenue primarily from its Software & Programming segment, which amounts to A$237.49 million.
Estimated Discount To Fair Value:49.2%
Nuix is trading at A$1.26, well below its estimated future cash flow value of A$2.47, indicating potential undervaluation. Earnings are forecast to grow significantly at 29.9% annually, outpacing the Australian market's average growth rate of 12.2%. Despite recent index exclusions, Nuix has become profitable with a net income of A$11.08 million for the half-year ending December 2025 and has strengthened its board with strategic appointments to enhance growth and governance capabilities.
-
Our earnings growth report unveils the potential for significant increases in Nuix's future results.
-
Delve into the full analysis health report here for a deeper understanding of Nuix.
Taking Advantage
-
Dive into all 49 of the Undervalued ASX Stocks Based On Cash Flows we have identified here.
-
Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
-
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Seeking Other Investments?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:CGS ASX:IDX and ASX:NXL.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
